ALECENSA Delivered Unprecedented First-Line Efficacy for Patients With ALK+ NSCLC vs Crizotinib[6,7]

ALECENSA delivered superior first-line median PFS of 34.8 months vs crizotinib[1]

INV
DATA CUTOFF: DEC. 1, 2017

ALECENSA (n=152)		crizotinib (n=151)	
34.8 months median PFS	vs	**10.9** months median PFS	**57%** REDUCTION IN RISK
(95% CI: 17.7, NE)		(95% CI: 9.1, 12.9)	HR=0.43 (95% CI: 0.32, 0.58)

ALECENSA has been proven to protect against the onset of new CNS metastases[2]

PRIMARY ANALYSIS

(PERCENTAGE OF PATIENTS WITH FIRST PROGRESSION IN THE CNS (N=303

ALECENSA (n=152)		crizotinib (n=151)	
12%	vs	**45%**	**84%** REDUCTION IN RISK
(n=18/152)		(n=68/151)	HR=0.16 (95% CI: 0.10, 0.28) *P*<0.0001

ALECENSA demonstrated favourable safety and tolerability vs crizotinib[3]

ALK=anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer

Roche Pharmaceuticals (Israel) Ltd

ALE-1811-V2-2761

ALECENSA®
alectinib 150 mg capsules